Changes and Challenges

Rüdiger E. Scharf

In the past year, several significant changes have occurred to the Journal and its Editorial Board. Most important among these changes is that Schattauer was acquired by Thieme at the end of 2017 and that the Thieme Publishers has become the new partner of Hämostaseologie – Progress in Haemostasis as of January 1, 2018.

• References

• 1 Scharf RE. Awareness and attraction or adhesion and activation. Hämostaseologie 2018; 38 (01) 5-6
• 2 Scharf RE. Pictures tell their own story. Images in Thrombosis & Haemostasis Editorial. Hämostaseologie 2017; 37 (03) 181-183
• 3 Klamroth R, Koscielny J. Science meets clinical practice. The 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research. Editorial. Hämostaseologie 2019; 39 (01) 4-5
• 4 Zaninetti C, De Rocco D, Giangregorio T. , et al. MYH9-related thrombocytopenia: four novel variants affecting the tail domain of the non-muscle myosin heavy chain IIA associated with a mild clinical evolution of the disorder. Hämostaseologie 2019; 39 (01) 87-94
• 5 Seri M, Cusano R, Gangarossa S. , et al; The May-Heggllin/Fechtner Syndrome Consortium. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. Nat Genet 2000; 26 (01) 103-105
• 6 Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010; 17 (05) 405-410
• 7 Sacco C, Zane F, Granziera S. , et al. Barco S on behalf of the Lemierre Study Group. Lemierre syndrome: clinical update and protocol for a systemic review and individual patient data meta-analysis. Hämostaseologie 2019; 39 (01) 76-86
• 8 Lemierre A. On certain septicaemias due to anaerobic organisms. Lancet 1936; 1: 701-703
• 9 Gheisari R, Bomke B, Hoffmann T, Scharf RE. Clinical features and outcome of acquired haemophilia A. Interim analysis of the Düsseldorf study. Hämostaseologie 2010; 30 (03) 156-161
• 10 Tiede A, Klamroth R, Scharf RE. , et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125 (07) 1091-1097
• 11 Tiede A, Scharf RE, Dobbelstein C, Werwitzke S. Management of acquired haemophilia A. Hämostaseologie 2015; 35 (04) 311-318
• 12 Tiede A, Hofbauer CJ, Werwitzke S. , et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood 2016; 127 (19) 2289-2297
• 13 Werwitzke S, Geisen U, Nowak-Göttl U. , et al. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. J Thromb Haemost 2016; 14 (05) 940-947
• 14 Pacholczak R, Bazan-Socha S, Zdziarska J. , et al. Acquired haemophilia A associated with subsequent hepatocellular carcinoma. Hämostaseologie 2019; 39 (01) 95-99